Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
The Lancet Oncology.
Times cited: 82
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial.
Journal of Clinical Oncology.
Times cited: 116
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Times cited: 39